author-photo

Jules Blank

University of Wisconsin-Madison

16

Papers

366

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (11)
Panobinostat, a novel histone deacetylase inhibitor, in advanced medullary and iodine-refractory differentiated thyroid cancer: A Wisconsin Oncology Network trial.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study

2016 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (11)
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

2015 Cancer
Show All
- Source
- Cite
- Save
Citations (30)
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

2014 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (29)
Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.

2011 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (37)
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.

2011 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (45)
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer

2008 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (46)
VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

2008 Blood
Show All
- Source
- Cite
- Save
Citations (16)